Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · December 01, 2021

Asciminib vs Bosutinib in CML After Two or More Prior TKIs



Additional Info

A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs
Blood 2021 Nov 25;138(21)2031-2041, D Réa, MJ Mauro, C Boquimpani, Y Minami, E Lomaia, S Voloshin, A Turkina, DW Kim, JF Apperley, A Abdo, LM Fogliatto, DDH Kim, P le Coutre, S Saussele, M Annunziata, TP Hughes, N Chaudhri, K Sasaki, L Chee, V García-Gutiérrez, JE Cortes, P Aimone, A Allepuz, S Quenet, V Bédoucha, A Hochhaus

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading